We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Hutchmed (china) Limited | HCM | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -14.00 | -4.61% | 290.00 | 16:22:23 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 312.00 | 287.00 | 312.00 | 290.00 | 304.00 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 26/4/2024 17:15 by dbadvn US investors so spooked over China that all they are looking at is the money.When the cash starts tocome in they will react. In the meantime HCM remains a huge bargain. |
Posted at 25/4/2024 09:30 by 1jat AZ reported Q1 Orpathys sales up 43% (48% at CER). HCM gets a large % of the revenue in royalties and manufacturing fees.Sales continue to build after inclusion in NRDL. |
Posted at 02/4/2024 06:00 by lauders More good news from HCM today: HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status |
Posted at 12/3/2024 09:43 by 1jat I am not sure these moves on no news really mean anything…and could well be reversed tomorrow when the market takes fright at some statement coming from US/China that indicates more restrictions.The next news I will be looking for will be from Takeda… Their annual results are due in early/mid May and will contain the $15m sales from 2023 disclosed by HCM and the first three months of 2024. There may have been some stocking within the $15m and conversion of those on early access programs, but I hope they can sell $30m in Q1 and build to a $50m/quarter during 2024. This would give US in market sales of $150-180 and a $20m royalty (pure profit) to HCM (plus manufacturing fees). It was interesting to see in the company presentation that Europe is potentially a much larger market than the US. It did not appear that the EMA was giving priority status, so they may take longer than the US to approve…that will also be good news when it comes. |
Posted at 28/2/2024 12:23 by dbadvn I have stuck with HCM through everything because in the end the story has not changed.Management has been ropey at times, but they are delivering the products and the cash is now coming in. Only politics holding them back and they are working their way round that. |
Posted at 08/2/2024 09:33 by 1jat AZ reporting $44m of orpathys sales.This would imply $30m revenue for HCM as flat on H1. |
Posted at 03/2/2024 00:47 by lauders More positive news yesterday and no positive impact on the share price. HCM really are in a rut at the moment. Thought 2024 was going to be better, but still 11 months to go. |
Posted at 29/1/2024 14:46 by nerdofsteel "But hcm still irritates you"not really, I was just posting an observation about geo-politics at play here and yes I have sold, but I may well buy back in if things begin to improve. In the meantime I've made a packet on Nvidia, more in a month than I have being invested in HCM over 7 years... |
Posted at 28/1/2024 18:23 by 1jat Lauders - I agree with your sentiment but it could be some time in coming… the macro environment is again at play - I read a US congressman has tabled a bill to sanction certain Chinese Biopharma due to links to the China Army….which cannot be helping US investors.I doubt many investors in smaller pharma are actually expecting/wanting them to transition into self supporting larger pharma cos. It is not clear what CKHH position is….they seem to be happy to hold and see the company grow - they dont currently need any cash from their stake, this effectively means HCM is not for sale. If the Vodafone/3 deal goes through CKHH will pocket a couple of Billion and have options to sell out in 2-3 years…. I expect there will be M&A within China biopharma soon…..many companies have cash for a couple of years if fund raising becomes more difficult they will have to be sold…HCM may get to self sustainability before this happens which will put them into a stronger position to buy. |
Posted at 22/1/2024 22:45 by mcmather US closed -7.50%. Will we see any response from the company?There appeared to be support on the US weekly at 14.48ish. Hmmmm. FWIW: "The 55 rating InvestorsObserver gives to HUTCHMED (China) Ltd (HCM) stock puts it near the top of the Drug Manufacturers - Specialty & Generic industry. In addition to scoring higher than 80 percent of stocks in the Drug Manufacturers - Specialty & Generic industry, HCM’s 55 overall rating means the stock scores better than 55 percent of all stocks...Over the past year the S&P 500 has risen 20.68% while HCM has fallen -26.98%" |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
